The North American pharmaceutical company today announced the request for emergency use of its vaccine for covid-19 to European and North American medicine regulators.
The company also revealed that the final results of clinical trials of the vaccine against the new coronavirus indicate an effectiveness of 94,1 percent.
The efficacy and safety shown by the vaccine - which caused temporary side effects similar to flu symptoms - meet the requirements of the US agency, the FDA, for an emergency use authorization even before the entire testing phase is complete.
The European Medicines Agency has also expressed its openness to authorize the use of the drug.
Moderna revealed that there are no safety problems with its vaccine, with side effects and limited to momentary pain at the injection site, headaches and fatigue.
The announcement of the approval request came shortly after another similar one made by pharmaceutical companies Pfizer and BioNTech, whose vaccines, such as Moderna's, use messenger RNA technology, a new technique that allows the use of a cellular protein generation mechanism to generate the desired immunity response against a virus like SARS-CoV-2.
Moderna's vaccine, however, does not need minus 70 degrees below zero, as is the case with Pfizer, so its transport and storage would be cheaper and more accessible to rural areas or developing economies.
After announcing that they would proceed with the order, the pharmaceutical company's shares appreciated 11% in the negotiations before the market opened. Thus, Moderna's shares are now valued at $ 141,40 (€ 118,06).
